Date: 2015-10-07
Type of information: Services contract
Compound: in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services
Company: Charles River (USA - MA) Antabio (France)
Therapeutic area: Infectious diseases - Technology - Services
Type agreement: services contract
Action mechanism:
Disease:
Details: * On October 7, 2015, Charles River Laboratories International announced new and continuing collaborations with three innovative drug discovery partners funded by the Wellcome Trust. Antabio, an anti-bacterial drug discovery company, Pcovery, a spin-out company focused on anti-fungals, and the British Columbia Cancer Agency have all extended existing or commenced new agreements with Charles River’s Global Discovery Services business.
As part of the agreements, Charles River’s Discovery Business will provide a comprehensive suite of in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services. For Antabio, Charles River will begin a new project developing a novel drug for infections in cystic fibrosis patients with project management, CADD, and medicinal and synthetic chemistry input. Charles River will also continue providing Antabio with medicinal and synthetic chemistry, CADD, and in vitro and in vivo DMPK services to develop drug candidates that inhibit antibiotic resistance.
Financial terms:
Latest news:
